Literature DB >> 19145963

Management of blood glucose in type 2 diabetes mellitus.

Cynthia M Ripsin1, Helen Kang, Randall J Urban.   

Abstract

Evidence-based guidelines for the treatment of type 2 diabetes mellitus focus on three areas: intensive lifestyle intervention that includes at least 150 minutes per week of physical activity, weight loss with an initial goal of 7 percent of baseline weight, and a low-fat, reduced-calorie diet; aggressive management of cardiovascular risk factors (i.e., hypertension, dyslipidemia, and microalbuminuria) with the use of aspirin, statins, and angiotensin-converting enzyme inhibitors; and normalization of blood glucose levels (hemoglobin A1C level less than 7 percent). Insulin resistance, decreased insulin secretion, and increased hepatic glucose output are the hallmarks of type 2 diabetes, and each class of medication targets one or more of these defects. Metformin, which decreases hepatic glucose output and sensitizes peripheral tissues to insulin, has been shown to decrease mortality rates in patients with type 2 diabetes and is considered a first-line agent. Other medications include sulfonylureas and nonsulfonylurea secretagogues, alpha glucosidase inhibitors, and thiazolidinediones. Insulin can be used acutely in patients newly diagnosed with type 2 diabetes to normalize blood glucose, or it can be added to a regimen of oral medication to improve glycemic control. Except in patients taking multiple insulin injections, home monitoring of blood glucose levels has questionable utility, especially in relatively well-controlled patients. Its use should be tailored to the needs of the individual patient.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19145963

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  53 in total

Review 1.  Path of translational discovery of urological complications of obesity and diabetes.

Authors:  Firouz Daneshgari; Guiming Liu; Ann T Hanna-Mitchell
Journal:  Am J Physiol Renal Physiol       Date:  2017-01-04

2.  Type 2 diabetes mellitus: a review of current trends.

Authors:  Abdulfatai B Olokoba; Olusegun A Obateru; Lateefat B Olokoba
Journal:  Oman Med J       Date:  2012-07

3.  Perceptions of physical activity and motivational interviewing among rural African-American women with type 2 diabetes.

Authors:  Stephania T Miller; Khensani N Marolen; Bettina M Beech
Journal:  Womens Health Issues       Date:  2009-11-26

Review 4.  Management of the metabolic syndrome and type 2 diabetes through lifestyle modification.

Authors:  Faidon Magkos; Mary Yannakoulia; Jean L Chan; Christos S Mantzoros
Journal:  Annu Rev Nutr       Date:  2009       Impact factor: 11.848

5.  Diabetes diagnosis and exercise initiation among older Americans.

Authors:  Leigh Ann Leung; Shailender Swaminathan; Amal N Trivedi
Journal:  Prev Med       Date:  2014-05-10       Impact factor: 4.018

6.  The Murphy Roths Large (MRL) mouse strain is naturally resistant to high fat diet-induced hyperglycemia.

Authors:  Aaron J Mull; Tirsit K Berhanu; Nathan W Roberts; Ahlke Heydemann
Journal:  Metabolism       Date:  2014-09-26       Impact factor: 8.694

7.  Outcome after curative surgery for gastric cancer patients with type 2 diabetes.

Authors:  Kuo-Chung Wang; Kuo-Hung Huang; Yuan-Tzu Lan; Wen-Liang Fang; Su-Shun Lo; Anna Fen-Yau Li; Chew-Wun Wu
Journal:  World J Surg       Date:  2014-02       Impact factor: 3.352

Review 8.  Drug rechanneling: A novel paradigm for cancer treatment.

Authors:  Itishree Kaushik; Sharavan Ramachandran; Sahdeo Prasad; Sanjay K Srivastava
Journal:  Semin Cancer Biol       Date:  2020-05-11       Impact factor: 15.707

9.  Pharmacogenomics in type II diabetes mellitus management: Steps toward personalized medicine.

Authors:  Peter Avery; Shaymaa S Mousa; Shaker A Mousa
Journal:  Pharmgenomics Pers Med       Date:  2009-09-13

10.  Association of rs7903146 (IVS3C/T) and rs290487 (IVS3C/T) polymorphisms in TCF7L2 with type 2 diabetes in 9,619 Han Chinese population.

Authors:  Jinjin Wang; Linlin Li; Jiatong Zhang; Jing Xie; Xinping Luo; Dahai Yu; Jingzhi Zhao; Tianping Feng; Chao Pang; Lei Yin; Fulan Hu; Jianfeng Zhang; Yan Wang; Qian Wang; Yujia Zhai; Haifei You; Tian Zhu; Dongsheng Hu
Journal:  PLoS One       Date:  2013-03-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.